EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Integrating Phosphatidylethanol to Enhance Alcohol Quantification in Steatotic Liver Disease and Clinical Trials

Elias D Rady iD, Thomas G Cotter iD

Liver International · 2026-01 · 46 (1)

DOI: 10.1111/liv.70489 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 22.12.2025. Verfasst von Elias D Rady und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Glycerophospholipids, Alcohol Drinking, Fatty Liver. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, National Institute on Alcohol Abuse and Alcoholism, American Association for the Study of Liver Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accurate quantification of alcohol intake is essential for the diagnosis, subclassification, and management of steatotic liver disease (SLD). In everyday clinical practice, alcohol histories rely primarily on physician‐assisted self‐report, with validated questionnaires used variably. Both provider‐level inconsistencies in documentation and patient‐level factors (e.g., recall and social‐desirability biases) can contribute to misclassification of SLD subtypes. Phosphatidylethanol (PEth), a direct alcohol biomarker detectable for ~2–4 weeks, has emerged as a promising objective tool that can complement self‐report. Across diverse SLD populations, PEth consistently uncovers underreported alcohol use, sharpens subclassification, informs prognosis, and enables longitudinal monitoring to guide care. In liver transplantation, PEth supports documentation of abstinence and detection of relapse to enable timely intervention. This mini‐review synthesises current evidence on PEth in SLD, emphasises its value in both clinical and research settings, and outlines priorities for integrating PEth into structured care pathways and clinical trial design to improve outcomes and harmonise endpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlycerophospholipidsAlcohol DrinkingFatty LiverHumansBiomarkersLiver TransplantationClinical Trials as TopicSelf Report

Stichwörter der Autor:innen

ALD: alcohol‐associated liver diseaseAUDIT‐C: alcohol use disorders identification test–consumptionMASLD: metabolic dysfunction‐associated Steatotic liver diseaseMetALD: metabolic dysfunction and alcohol‐associated liver diseasePEth: phosphatidylethanolSLD: steatotic liver diseaseTLFB: Timeline Followback

Substanzen

phosphatidylethanolGlycerophospholipidsBiomarkers

Autor:innen und Institutionen

  • Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Evidentis Clinical Research, Fort Worth, Texas, USA.

ORCID-Profile: Elias D Rady, Thomas G Cotter

Förderung

  • NIAAA NIH HHS
  • National Institute on Alcohol Abuse and Alcoholism
  • American Association for the Study of Liver Diseases

Zitieren

APA

Rady, E. D., & Cotter, T. G. (2026). Integrating Phosphatidylethanol to Enhance Alcohol Quantification in Steatotic Liver Disease and Clinical Trials. Liver International, 46(1). https://doi.org/10.1111/liv.70489

Vancouver

Rady ED, Cotter TG. Integrating Phosphatidylethanol to Enhance Alcohol Quantification in Steatotic Liver Disease and Clinical Trials. Liver International. 2026;46(1). doi:10.1111/liv.70489

BibTeX
@article{Rady2026,
  author = {Rady, Elias D and Cotter, Thomas G},
  title = {Integrating Phosphatidylethanol to Enhance Alcohol Quantification in Steatotic Liver Disease and Clinical Trials},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {1},
  doi = {10.1111/liv.70489}
}
Kostenlos starten →